Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.
Stolfi, C., Pallone, F., Macdonald, T., Monteleone, G. (2012). Interleukin-21 in cancer immunotherapy: Friend or foe?. ONCOIMMUNOLOGY, 1(3), 351-354 [10.4161/onci.19122].
Interleukin-21 in cancer immunotherapy: Friend or foe?
Stolfi, C
;PALLONE, FRANCESCO;MONTELEONE, GIOVANNI
2012-05-01
Abstract
Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
